Herpes Zoster Drug Market Analysis 2021-2031 | Trends
The Herpes Zoster Drug Market is expected to register a CAGR of 6.9% from 2023 to 2031, with a market size expanding from US$ XX million in 2023 to US$ XX Million by 2031.
The report is segmented by Drug (Anti-Viral Agents, Anti-Inflammatory Agents, Analgesics, Anticonvulsants Agents, Corticosteroids, Tricyclic Antidepressants, Antihistamines, Others). The report is segmented by Vaccine (Zostavax, Shingrix, Others). The report further presents analysis based on the Route of administration (Oral, Topical, Intravenous, Others). The report is segmented by Distribution Channel (Online Pharmacy, Retailers, Others). The report further presents analysis based on the End Users (Hospitals, Homecare, Specialty Clinics, Others). The global analysis is further broken-down at regional level and major countries. The Report Offers the Value in USD for the above analysis and segments.
Purpose of the ReportThe report Herpes Zoster Drug Market by The Insight Partners aims to describe the present landscape and future growth, top driving factors, challenges, and opportunities. This will provide insights to various business stakeholders, such as:
- Technology Providers/Manufacturers: To understand the evolving market dynamics and know the potential growth opportunities, enabling them to make informed strategic decisions.
- Investors: To conduct a comprehensive trend analysis regarding the market growth rate, market financial projections, and opportunities that exist across the value chain.
- Regulatory bodies: To regulate policies and police activities in the market with the aim of minimizing abuse, preserving investor trust and confidence, and upholding the integrity and stability of the market.
Herpes Zoster Drug Market Segmentation
Drug- Anti-Viral Agents
- Anti-Inflammatory Agents
- Analgesics
- Anticonvulsants Agents
- Corticosteroids
- Tricyclic Antidepressants
- Antihistamines
- Others
- Zostavax
- Shingrix
- Others
- Oral
- Topical
- Intravenous
- Others
- Online Pharmacy
- Retailers
- Others
- Online Pharmacy
- Retailers
- Others
Strategic Insights
Herpes Zoster Drug Market Growth Drivers- Rising Incidence of Herpes Zoster: Increasing Herpes Zoster incidence is one of the foremost contributors to the market for herpes zoster drugs. The increase ties to the older population, as most repercussions of this disease are into adults above fifty years old in age. The more the aging population increases in developed countries, the more people are likely to suffer from shingles; moreover, even other causes making the immunocompromised population grow, such as HIV, treatments for cancers, and organ transplants, would make the burden of Herpes Zoster incidence increase. Hence, growing demand is expected for vaccines and antiviral treatments that will help reduce outbreak frequency and severity.
- Advancement of Vaccine Development: New vaccine formulations are propelling the herpes zoster drug market substantially. The use of far more effective vaccines, such as the recombinant zoster vaccine (Shingrix), has changed the landscape of preventive measures against shingles completely. The efficacy rates of Shingrix exceed those of its predecessor, Zostavax, especially in older adults thus resulting in a higher appropriation. These preventive vaccines are what provide market impetus whereby an individual can try to avoid contracting herpes zoster.
- Awareness and Early Diagnosis Extension: Increased recognition of herpes zoster symptoms and their subsequent effects, such as post-herpetic neuralgia (PHN), brought early more patients to health care systems. Earlier diagnosis would allow early treatment with reduced symptoms' severity and duration. Today, more health professionals prescribe antivirals including acyclovir, valacyclovir, and famciclovir, contributing to a shorter recovery period for the patients while minimizing complication rates. The push for early diagnosis and treatment will definitely boost diagnosis.
- Tailored Treatment Strategies: Personalized Therapy Development in herpes zoster. The advances in genomics and patient-specific medicine have made the patient-specific approaches more popular for herpes zoster treatment. Medical professionals have been using variables such as age, immunity status, and other underlying conditions to determine the best antiviral or vaccine treatment regimen with regard to individual patients. This strategy enables better management and less chance of complications like post-herpetic neuralgia (PHN), highly prevalent in elderly patients. Individualized vaccine strategies are also being researched, intending to make better the overall integrity of results and patient outcomes.
- Combination Therapy: Another emerging modality for the treatment of herpes zoster and for preventing complications is through combination therapy. The antiviral is sometimes given together with a medication for pain management, such as corticosteroids or neuropathic pain medications, to help avoid the extreme nerve pain that often accompanies the condition. Combination therapies aim at treating symptoms optimally, thus becoming a great new trend in the market.
- Increased Availability of Vaccines: The increasing trend towards an availability of vaccines beyond the old marketplaces is becoming visible on the market. For instance, vaccines like Shingrix have been dedicated only to developed markets at launch stages, while emerging economies also approved and introduced them into circulation. They are improving the numbers of preventive measures worldwide as they become more available globally, especially among the older populations in those countries with a vast demographic of the elderly.
- Growth in Geriatric Population: The influx of the aging population has widened avenues for the herpes zoster pharmaceutical market. As one grows older, one would suffer a dip in immunity, hence increasing chances of shingles developing. By 2050, the population in the category of 65 years and above is expected to double, raising the overall population at risk of herpes zoster substantially. There are, thus, vast opportunities for pharmaceutical companies to target older populations through vaccine- and drug-based therapies, driving growth for the herpes zoster drug market for years to come.
- Development of Modern Drug Delivery Systems New drug delivery systems like transdermal patches or microneedle patches are invented to increase efficacy and convenience for herpes zoster treatment. These innovations open opportunities for the use of antiviral drugs and vaccines made easier and more applicable for those who may be afraid of needle-based injections. The establishment of such infrastructures would favor wider uptake of preventions as well as treatment.
- Strategic partnerships: Partnerships of pharmaceutical organizations and health care organizations will create opportunities in the development and marketing of treatments for herpes zoster. Collaborations offer both research into new antiviral agents and work on better vaccine formulations, which will bring underserved markets into the fold. This will enable companies to discover new markets and expedite the global introduction of innovative treatments and vaccines.
Market Report Scope
Key Selling Points
- Comprehensive Coverage: The report comprehensively covers the analysis of products, services, types, and end users of the Herpes Zoster Drug Market, providing a holistic landscape.
- Expert Analysis: The report is compiled based on the in-depth understanding of industry experts and analysts.
- Up-to-date Information: The report assures business relevance due to its coverage of recent information and data trends.
- Customization Options: This report can be customized to cater to specific client requirements and suit the business strategies aptly.
The research report on the Herpes Zoster Drug Market can, therefore, help spearhead the trail of decoding and understanding the industry scenario and growth prospects. Although there can be a few valid concerns, the overall benefits of this report tend to outweigh the disadvantages.
REGIONAL FRAMEWORK
Have a question?
Mrinal
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
Anti-Viral Agents segment, by drug, dominated the market in 2023.
Players operating in the market are Pfizer Inc, Abbott, Novartis AG, Merck & Co., Inc., GlaxoSmithKline plc, F. Hoffmann,La Roche Ltd, Bristol, Myers Squibb Company, Astellas Pharma Inc., GeneOne Life Science, Camber Pharmaceuticals
North America region dominated the Herpes Zoster Drug market in 2023.
Growth in Geriatric Population act as a opportunity for growth of the market in forecast period.
The Herpes Zoster Drug Market is estimated to witness a CAGR of 6.9% from 2023 to 2031
The major factors driving the Herpes Zoster Drug market are:
1. Rising Incidence of Herpes Zoster
2. Advancement of Vaccine Development
1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Herpes Zoster Drug Market - By Drug
1.3.2 Herpes Zoster Drug Market - By Vaccine
1.3.3 Herpes Zoster Drug Market - By Route of administration
1.3.4 Herpes Zoster Drug Market - By Distribution Channel
1.3.5 Herpes Zoster Drug Market - By End Users
1.3.6 Herpes Zoster Drug Market - By Region
1.3.6.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. HERPES ZOSTER DRUG MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PORTER'S FIVE FORCES ANALYSIS
4.2.1 Bargaining Power of Buyers
4.2.1 Bargaining Power of Suppliers
4.2.1 Threat of Substitute
4.2.1 Threat of New Entrants
4.2.1 Competitive Rivalry
4.3. EXPERT OPINIONS
5. HERPES ZOSTER DRUG MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. HERPES ZOSTER DRUG MARKET - GLOBAL MARKET ANALYSIS
6.1. HERPES ZOSTER DRUG - GLOBAL MARKET OVERVIEW
6.2. HERPES ZOSTER DRUG - GLOBAL MARKET AND FORECAST TO 2028
6.3. MARKET POSITIONING/MARKET SHARE
7. HERPES ZOSTER DRUG MARKET - REVENUE AND FORECASTS TO 2028 - DRUG
7.1. OVERVIEW
7.2. DRUG MARKET FORECASTS AND ANALYSIS
7.3. ANTI-VIRAL AGENTS
7.3.1. Overview
7.3.2. Anti-Viral Agents Market Forecast and Analysis
7.4. ANTI-INFLAMMATORY AGENTS
7.4.1. Overview
7.4.2. Anti-Inflammatory Agents Market Forecast and Analysis
7.5. ANALGESICS
7.5.1. Overview
7.5.2. Analgesics Market Forecast and Analysis
7.6. ANTICONVULSANTS AGENTS
7.6.1. Overview
7.6.2. Anticonvulsants Agents Market Forecast and Analysis
7.7. CORTICOSTEROIDS
7.7.1. Overview
7.7.2. Corticosteroids Market Forecast and Analysis
7.8. TRICYCLIC ANTIDEPRESSANTS
7.8.1. Overview
7.8.2. Tricyclic Antidepressants Market Forecast and Analysis
7.9. ANTIHISTAMINES
7.9.1. Overview
7.9.2. Antihistamines Market Forecast and Analysis
7.10. OTHERS
7.10.1. Overview
7.10.2. Others Market Forecast and Analysis
8. HERPES ZOSTER DRUG MARKET - REVENUE AND FORECASTS TO 2028 - VACCINE
8.1. OVERVIEW
8.2. VACCINE MARKET FORECASTS AND ANALYSIS
8.3. ZOSTAVAX
8.3.1. Overview
8.3.2. Zostavax Market Forecast and Analysis
8.4. SHINGRIX
8.4.1. Overview
8.4.2. Shingrix Market Forecast and Analysis
8.5. OTHERS
8.5.1. Overview
8.5.2. Others Market Forecast and Analysis
9. HERPES ZOSTER DRUG MARKET - REVENUE AND FORECASTS TO 2028 - ROUTE OF ADMINISTRATION
9.1. OVERVIEW
9.2. ROUTE OF ADMINISTRATION MARKET FORECASTS AND ANALYSIS
9.3. ORAL
9.3.1. Overview
9.3.2. Oral Market Forecast and Analysis
9.4. TOPICAL
9.4.1. Overview
9.4.2. Topical Market Forecast and Analysis
9.5. INTRAVENOUS
9.5.1. Overview
9.5.2. Intravenous Market Forecast and Analysis
9.6. OTHERS
9.6.1. Overview
9.6.2. Others Market Forecast and Analysis
10. HERPES ZOSTER DRUG MARKET - REVENUE AND FORECASTS TO 2028 - DISTRIBUTION CHANNEL
10.1. OVERVIEW
10.2. DISTRIBUTION CHANNEL MARKET FORECASTS AND ANALYSIS
10.3. ONLINE PHARMACY
10.3.1. Overview
10.3.2. Online Pharmacy Market Forecast and Analysis
10.4. RETAILERS
10.4.1. Overview
10.4.2. Retailers Market Forecast and Analysis
10.5. OTHERS
10.5.1. Overview
10.5.2. Others Market Forecast and Analysis
11. HERPES ZOSTER DRUG MARKET - REVENUE AND FORECASTS TO 2028 - END USERS
11.1. OVERVIEW
11.2. END USERS MARKET FORECASTS AND ANALYSIS
11.3. HOSPITALS
11.3.1. Overview
11.3.2. Hospitals Market Forecast and Analysis
11.4. HOMECARE
11.4.1. Overview
11.4.2. Homecare Market Forecast and Analysis
11.5. SPECIALTY CLINICS
11.5.1. Overview
11.5.2. Specialty Clinics Market Forecast and Analysis
11.6. OTHERS
11.6.1. Overview
11.6.2. Others Market Forecast and Analysis
12. HERPES ZOSTER DRUG MARKET REVENUE AND FORECASTS TO 2028 - GEOGRAPHICAL ANALYSIS
12.1. NORTH AMERICA
12.1.1 North America Herpes Zoster Drug Market Overview
12.1.2 North America Herpes Zoster Drug Market Forecasts and Analysis
12.1.3 North America Herpes Zoster Drug Market Forecasts and Analysis - By Drug
12.1.4 North America Herpes Zoster Drug Market Forecasts and Analysis - By Vaccine
12.1.5 North America Herpes Zoster Drug Market Forecasts and Analysis - By Route of administration
12.1.6 North America Herpes Zoster Drug Market Forecasts and Analysis - By Distribution Channel
12.1.7 North America Herpes Zoster Drug Market Forecasts and Analysis - By End Users
12.1.8 North America Herpes Zoster Drug Market Forecasts and Analysis - By Countries
12.1.8.1 Canada Herpes Zoster Drug Market
12.1.8.1.1 Canada Herpes Zoster Drug Market by Drug
12.1.8.1.2 Canada Herpes Zoster Drug Market by Vaccine
12.1.8.1.3 Canada Herpes Zoster Drug Market by Route of administration
12.1.8.1.4 Canada Herpes Zoster Drug Market by Distribution Channel
12.1.8.1.5 Canada Herpes Zoster Drug Market by End Users
12.1.8.2 Mexico Herpes Zoster Drug Market
12.1.8.2.1 Mexico Herpes Zoster Drug Market by Drug
12.1.8.2.2 Mexico Herpes Zoster Drug Market by Vaccine
12.1.8.2.3 Mexico Herpes Zoster Drug Market by Route of administration
12.1.8.2.4 Mexico Herpes Zoster Drug Market by Distribution Channel
12.1.8.2.5 Mexico Herpes Zoster Drug Market by End Users
12.1.8.3 US Herpes Zoster Drug Market
12.1.8.3.1 US Herpes Zoster Drug Market by Drug
12.1.8.3.2 US Herpes Zoster Drug Market by Vaccine
12.1.8.3.3 US Herpes Zoster Drug Market by Route of administration
12.1.8.3.4 US Herpes Zoster Drug Market by Distribution Channel
12.1.8.3.5 US Herpes Zoster Drug Market by End Users
12.2. EUROPE
12.2.1 Europe Herpes Zoster Drug Market Overview
12.2.2 Europe Herpes Zoster Drug Market Forecasts and Analysis
12.2.3 Europe Herpes Zoster Drug Market Forecasts and Analysis - By Drug
12.2.4 Europe Herpes Zoster Drug Market Forecasts and Analysis - By Vaccine
12.2.5 Europe Herpes Zoster Drug Market Forecasts and Analysis - By Route of administration
12.2.6 Europe Herpes Zoster Drug Market Forecasts and Analysis - By Distribution Channel
12.2.7 Europe Herpes Zoster Drug Market Forecasts and Analysis - By End Users
12.2.8 Europe Herpes Zoster Drug Market Forecasts and Analysis - By Countries
12.2.8.1 Germany Herpes Zoster Drug Market
12.2.8.1.1 Germany Herpes Zoster Drug Market by Drug
12.2.8.1.2 Germany Herpes Zoster Drug Market by Vaccine
12.2.8.1.3 Germany Herpes Zoster Drug Market by Route of administration
12.2.8.1.4 Germany Herpes Zoster Drug Market by Distribution Channel
12.2.8.1.5 Germany Herpes Zoster Drug Market by End Users
12.2.8.2 France Herpes Zoster Drug Market
12.2.8.2.1 France Herpes Zoster Drug Market by Drug
12.2.8.2.2 France Herpes Zoster Drug Market by Vaccine
12.2.8.2.3 France Herpes Zoster Drug Market by Route of administration
12.2.8.2.4 France Herpes Zoster Drug Market by Distribution Channel
12.2.8.2.5 France Herpes Zoster Drug Market by End Users
12.2.8.3 Italy Herpes Zoster Drug Market
12.2.8.3.1 Italy Herpes Zoster Drug Market by Drug
12.2.8.3.2 Italy Herpes Zoster Drug Market by Vaccine
12.2.8.3.3 Italy Herpes Zoster Drug Market by Route of administration
12.2.8.3.4 Italy Herpes Zoster Drug Market by Distribution Channel
12.2.8.3.5 Italy Herpes Zoster Drug Market by End Users
12.2.8.4 Spain Herpes Zoster Drug Market
12.2.8.4.1 Spain Herpes Zoster Drug Market by Drug
12.2.8.4.2 Spain Herpes Zoster Drug Market by Vaccine
12.2.8.4.3 Spain Herpes Zoster Drug Market by Route of administration
12.2.8.4.4 Spain Herpes Zoster Drug Market by Distribution Channel
12.2.8.4.5 Spain Herpes Zoster Drug Market by End Users
12.2.8.5 United Kingdom Herpes Zoster Drug Market
12.2.8.5.1 United Kingdom Herpes Zoster Drug Market by Drug
12.2.8.5.2 United Kingdom Herpes Zoster Drug Market by Vaccine
12.2.8.5.3 United Kingdom Herpes Zoster Drug Market by Route of administration
12.2.8.5.4 United Kingdom Herpes Zoster Drug Market by Distribution Channel
12.2.8.5.5 United Kingdom Herpes Zoster Drug Market by End Users
12.2.8.6 Rest of Europe Herpes Zoster Drug Market
12.2.8.6.1 Rest of Europe Herpes Zoster Drug Market by Drug
12.2.8.6.2 Rest of Europe Herpes Zoster Drug Market by Vaccine
12.2.8.6.3 Rest of Europe Herpes Zoster Drug Market by Route of administration
12.2.8.6.4 Rest of Europe Herpes Zoster Drug Market by Distribution Channel
12.2.8.6.5 Rest of Europe Herpes Zoster Drug Market by End Users
12.3. ASIA-PACIFIC
12.3.1 Asia-Pacific Herpes Zoster Drug Market Overview
12.3.2 Asia-Pacific Herpes Zoster Drug Market Forecasts and Analysis
12.3.3 Asia-Pacific Herpes Zoster Drug Market Forecasts and Analysis - By Drug
12.3.4 Asia-Pacific Herpes Zoster Drug Market Forecasts and Analysis - By Vaccine
12.3.5 Asia-Pacific Herpes Zoster Drug Market Forecasts and Analysis - By Route of administration
12.3.6 Asia-Pacific Herpes Zoster Drug Market Forecasts and Analysis - By Distribution Channel
12.3.7 Asia-Pacific Herpes Zoster Drug Market Forecasts and Analysis - By End Users
12.3.8 Asia-Pacific Herpes Zoster Drug Market Forecasts and Analysis - By Countries
12.3.8.1 Australia Herpes Zoster Drug Market
12.3.8.1.1 Australia Herpes Zoster Drug Market by Drug
12.3.8.1.2 Australia Herpes Zoster Drug Market by Vaccine
12.3.8.1.3 Australia Herpes Zoster Drug Market by Route of administration
12.3.8.1.4 Australia Herpes Zoster Drug Market by Distribution Channel
12.3.8.1.5 Australia Herpes Zoster Drug Market by End Users
12.3.8.2 China Herpes Zoster Drug Market
12.3.8.2.1 China Herpes Zoster Drug Market by Drug
12.3.8.2.2 China Herpes Zoster Drug Market by Vaccine
12.3.8.2.3 China Herpes Zoster Drug Market by Route of administration
12.3.8.2.4 China Herpes Zoster Drug Market by Distribution Channel
12.3.8.2.5 China Herpes Zoster Drug Market by End Users
12.3.8.3 India Herpes Zoster Drug Market
12.3.8.3.1 India Herpes Zoster Drug Market by Drug
12.3.8.3.2 India Herpes Zoster Drug Market by Vaccine
12.3.8.3.3 India Herpes Zoster Drug Market by Route of administration
12.3.8.3.4 India Herpes Zoster Drug Market by Distribution Channel
12.3.8.3.5 India Herpes Zoster Drug Market by End Users
12.3.8.4 Japan Herpes Zoster Drug Market
12.3.8.4.1 Japan Herpes Zoster Drug Market by Drug
12.3.8.4.2 Japan Herpes Zoster Drug Market by Vaccine
12.3.8.4.3 Japan Herpes Zoster Drug Market by Route of administration
12.3.8.4.4 Japan Herpes Zoster Drug Market by Distribution Channel
12.3.8.4.5 Japan Herpes Zoster Drug Market by End Users
12.3.8.5 South Korea Herpes Zoster Drug Market
12.3.8.5.1 South Korea Herpes Zoster Drug Market by Drug
12.3.8.5.2 South Korea Herpes Zoster Drug Market by Vaccine
12.3.8.5.3 South Korea Herpes Zoster Drug Market by Route of administration
12.3.8.5.4 South Korea Herpes Zoster Drug Market by Distribution Channel
12.3.8.5.5 South Korea Herpes Zoster Drug Market by End Users
12.3.8.6 Rest of Asia-Pacific Herpes Zoster Drug Market
12.3.8.6.1 Rest of Asia-Pacific Herpes Zoster Drug Market by Drug
12.3.8.6.2 Rest of Asia-Pacific Herpes Zoster Drug Market by Vaccine
12.3.8.6.3 Rest of Asia-Pacific Herpes Zoster Drug Market by Route of administration
12.3.8.6.4 Rest of Asia-Pacific Herpes Zoster Drug Market by Distribution Channel
12.3.8.6.5 Rest of Asia-Pacific Herpes Zoster Drug Market by End Users
12.4. MIDDLE EAST AND AFRICA
12.4.1 Middle East and Africa Herpes Zoster Drug Market Overview
12.4.2 Middle East and Africa Herpes Zoster Drug Market Forecasts and Analysis
12.4.3 Middle East and Africa Herpes Zoster Drug Market Forecasts and Analysis - By Drug
12.4.4 Middle East and Africa Herpes Zoster Drug Market Forecasts and Analysis - By Vaccine
12.4.5 Middle East and Africa Herpes Zoster Drug Market Forecasts and Analysis - By Route of administration
12.4.6 Middle East and Africa Herpes Zoster Drug Market Forecasts and Analysis - By Distribution Channel
12.4.7 Middle East and Africa Herpes Zoster Drug Market Forecasts and Analysis - By End Users
12.4.8 Middle East and Africa Herpes Zoster Drug Market Forecasts and Analysis - By Countries
12.4.8.1 South Africa Herpes Zoster Drug Market
12.4.8.1.1 South Africa Herpes Zoster Drug Market by Drug
12.4.8.1.2 South Africa Herpes Zoster Drug Market by Vaccine
12.4.8.1.3 South Africa Herpes Zoster Drug Market by Route of administration
12.4.8.1.4 South Africa Herpes Zoster Drug Market by Distribution Channel
12.4.8.1.5 South Africa Herpes Zoster Drug Market by End Users
12.4.8.2 Saudi Arabia Herpes Zoster Drug Market
12.4.8.2.1 Saudi Arabia Herpes Zoster Drug Market by Drug
12.4.8.2.2 Saudi Arabia Herpes Zoster Drug Market by Vaccine
12.4.8.2.3 Saudi Arabia Herpes Zoster Drug Market by Route of administration
12.4.8.2.4 Saudi Arabia Herpes Zoster Drug Market by Distribution Channel
12.4.8.2.5 Saudi Arabia Herpes Zoster Drug Market by End Users
12.4.8.3 U.A.E Herpes Zoster Drug Market
12.4.8.3.1 U.A.E Herpes Zoster Drug Market by Drug
12.4.8.3.2 U.A.E Herpes Zoster Drug Market by Vaccine
12.4.8.3.3 U.A.E Herpes Zoster Drug Market by Route of administration
12.4.8.3.4 U.A.E Herpes Zoster Drug Market by Distribution Channel
12.4.8.3.5 U.A.E Herpes Zoster Drug Market by End Users
12.4.8.4 Rest of Middle East and Africa Herpes Zoster Drug Market
12.4.8.4.1 Rest of Middle East and Africa Herpes Zoster Drug Market by Drug
12.4.8.4.2 Rest of Middle East and Africa Herpes Zoster Drug Market by Vaccine
12.4.8.4.3 Rest of Middle East and Africa Herpes Zoster Drug Market by Route of administration
12.4.8.4.4 Rest of Middle East and Africa Herpes Zoster Drug Market by Distribution Channel
12.4.8.4.5 Rest of Middle East and Africa Herpes Zoster Drug Market by End Users
12.5. SOUTH AND CENTRAL AMERICA
12.5.1 South and Central America Herpes Zoster Drug Market Overview
12.5.2 South and Central America Herpes Zoster Drug Market Forecasts and Analysis
12.5.3 South and Central America Herpes Zoster Drug Market Forecasts and Analysis - By Drug
12.5.4 South and Central America Herpes Zoster Drug Market Forecasts and Analysis - By Vaccine
12.5.5 South and Central America Herpes Zoster Drug Market Forecasts and Analysis - By Route of administration
12.5.6 South and Central America Herpes Zoster Drug Market Forecasts and Analysis - By Distribution Channel
12.5.7 South and Central America Herpes Zoster Drug Market Forecasts and Analysis - By End Users
12.5.8 South and Central America Herpes Zoster Drug Market Forecasts and Analysis - By Countries
12.5.8.1 Brazil Herpes Zoster Drug Market
12.5.8.1.1 Brazil Herpes Zoster Drug Market by Drug
12.5.8.1.2 Brazil Herpes Zoster Drug Market by Vaccine
12.5.8.1.3 Brazil Herpes Zoster Drug Market by Route of administration
12.5.8.1.4 Brazil Herpes Zoster Drug Market by Distribution Channel
12.5.8.1.5 Brazil Herpes Zoster Drug Market by End Users
12.5.8.2 Argentina Herpes Zoster Drug Market
12.5.8.2.1 Argentina Herpes Zoster Drug Market by Drug
12.5.8.2.2 Argentina Herpes Zoster Drug Market by Vaccine
12.5.8.2.3 Argentina Herpes Zoster Drug Market by Route of administration
12.5.8.2.4 Argentina Herpes Zoster Drug Market by Distribution Channel
12.5.8.2.5 Argentina Herpes Zoster Drug Market by End Users
12.5.8.3 Rest of South and Central America Herpes Zoster Drug Market
12.5.8.3.1 Rest of South and Central America Herpes Zoster Drug Market by Drug
12.5.8.3.2 Rest of South and Central America Herpes Zoster Drug Market by Vaccine
12.5.8.3.3 Rest of South and Central America Herpes Zoster Drug Market by Route of administration
12.5.8.3.4 Rest of South and Central America Herpes Zoster Drug Market by Distribution Channel
12.5.8.3.5 Rest of South and Central America Herpes Zoster Drug Market by End Users
13. INDUSTRY LANDSCAPE
13.1. MERGERS AND ACQUISITIONS
13.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
13.3. NEW PRODUCT LAUNCHES
13.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
14. HERPES ZOSTER DRUG MARKET, KEY COMPANY PROFILES
14.1. PFIZER INC
14.1.1. Key Facts
14.1.2. Business Description
14.1.3. Products and Services
14.1.4. Financial Overview
14.1.5. SWOT Analysis
14.1.6. Key Developments
14.2. ABBOTT
14.2.1. Key Facts
14.2.2. Business Description
14.2.3. Products and Services
14.2.4. Financial Overview
14.2.5. SWOT Analysis
14.2.6. Key Developments
14.3. NOVARTIS AG
14.3.1. Key Facts
14.3.2. Business Description
14.3.3. Products and Services
14.3.4. Financial Overview
14.3.5. SWOT Analysis
14.3.6. Key Developments
14.4. MERCK AND CO., INC.
14.4.1. Key Facts
14.4.2. Business Description
14.4.3. Products and Services
14.4.4. Financial Overview
14.4.5. SWOT Analysis
14.4.6. Key Developments
14.5. GLAXOSMITHKLINE PLC
14.5.1. Key Facts
14.5.2. Business Description
14.5.3. Products and Services
14.5.4. Financial Overview
14.5.5. SWOT Analysis
14.5.6. Key Developments
14.6. F. HOFFMANN-LA ROCHE LTD
14.6.1. Key Facts
14.6.2. Business Description
14.6.3. Products and Services
14.6.4. Financial Overview
14.6.5. SWOT Analysis
14.6.6. Key Developments
14.7. BRISTOL-MYERS SQUIBB COMPANY
14.7.1. Key Facts
14.7.2. Business Description
14.7.3. Products and Services
14.7.4. Financial Overview
14.7.5. SWOT Analysis
14.7.6. Key Developments
14.8. ASTELLAS PHARMA INC.
14.8.1. Key Facts
14.8.2. Business Description
14.8.3. Products and Services
14.8.4. Financial Overview
14.8.5. SWOT Analysis
14.8.6. Key Developments
14.9. GENEONE LIFE SCIENCE
14.9.1. Key Facts
14.9.2. Business Description
14.9.3. Products and Services
14.9.4. Financial Overview
14.9.5. SWOT Analysis
14.9.6. Key Developments
14.10. CAMBER PHARMACEUTICALS
14.10.1. Key Facts
14.10.2. Business Description
14.10.3. Products and Services
14.10.4. Financial Overview
14.10.5. SWOT Analysis
14.10.6. Key Developments
15. APPENDIX
15.1. ABOUT THE INSIGHT PARTNERS
15.2. GLOSSARY OF TERMS
- Pfizer Inc
- Abbott
- Novartis AG
- Merck & Co., Inc.
- GlaxoSmithKline plc
- F. Hoffmann-La Roche Ltd
- Bristol-Myers Squibb Company
- Astellas Pharma Inc.
- GeneOne Life Science
- Camber Pharmaceuticals
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Get Free Sample For